No Data
No Data
Unity Biotechnology Price Target Maintained With a $6.00/Share by Chardan Capital
Unity Biotechnology Is Maintained at Buy by Chardan Capital
Express News | UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.d., to the Board of Directors
Press Release: UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors
Express News | HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment